Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
97 hedge funds and large institutions have $154M invested in Concert Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 10 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
0% more funds holding
Funds holding: 97 → 97 (0)
2.26% less ownership
Funds ownership: 63.92% → 61.66% (-2.3%)
21% less capital invested
Capital invested by funds: $194M → $154M (-$40M)
29% less call options, than puts
Call options by funds: $17K | Put options by funds: $24K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ISL
Ingalls & Snyder LLC
New York
|
+$3.9M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.2M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$1.49M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.34M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$853K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Senzar Asset Management
New York
|
-$8.54M |
| 2 |
Millennium Management
New York
|
-$3.61M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.65M |
| 4 |
Morgan Stanley
New York
|
-$1.47M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.46M |
CNCE Hedge Fund Activity: Q2 2016 in Review
97 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2016, worth a combined $154M — down 21% from $194M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CNCE positions and 10 closed out — a net gain of 1 holder — while 39 added to existing stakes and 29 trimmed.
The largest buyer was Ingalls & Snyder LLC, adding an estimated $3.9M. The largest seller was Senzar Asset Management, cutting an estimated $8.54M.
- 97 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $154M of Concert Pharmaceuticals, Inc. stock for Q2 2016, down 21% quarter-over-quarter.
- 11 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2016 and 10 closed out, a net change of +1 holder.
- The largest Concert Pharmaceuticals, Inc. buyer in Q2 2016 was Ingalls & Snyder LLC, an estimated $3.9M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q2 2016 was Senzar Asset Management, an estimated $8.54M sold.
Based on aggregated 13F filings for Q2 2016.